LU X U RY PAC K AG IN G M A NUFAC TUR ER S P I R I T B O T T L E C A P S • Specific gravity of 1.6 • EU and FDA compliant material • ABS-based material suitable for electroplating • Delivered a customized density polymer that supported electroplating, resulting in both the look and feel of metal • Demonstrated experience and expertise in density-modified material technology and electroplating to reach application goals quickly and cost-effectively Gravi-Tech™ Density Modified Formulation KEY REQUIREMENTS WHY AVIENT?

LEARN MORE INDUSTRIAL HOUSING OEM U T I L I T Y B O X S T I F F E N E R • Meet material stiffness requirement of 12,000 MPa flex modulus • Stable raw material supply • Formulated a solution that meets economic and mechanical property requirements • Quickly sampled and qualified the new material at multiple facilities • Enabled manufacturing at scale by using packaging that minimized moisture uptake during transit and storage • Provided a stable supply of post-industrial recycled (PIR) PA66 to offset prime PA66 Nymax™ REC Glass-Filled Formulation KEY REQUIREMENTS WHY AVIENT?

FAMOUS TIER 2 COMPANY A U T O M O T I V E L I G H T I N G I R L E N S O F S E N S O R • High heat resistance up to 203°C • PESU base resin with high IR transmission • Visible light cannot pass through • Used rich experience with different IR transmission materials to support customer’s material design and test method • Customized color for IR transmittance, which allowed IR to pass through the plastic lamp without accumulating high heat Edgetek™ ET9400-8005 IR Formulation KEY REQUIREMENTS WHY AVIENT?

PHARMACEUTICAL PACKAGING OEM V I A L S , B O T T L E S & C O N T A I N E R S • Raw materials pre-tested to USP 661.1 and ICHQ3D guidelines • Stabilization during molding and sterilization processes for both opaque and transparent polymer materials • Certified formulations available globally • Offered pre-tested raw materials and produced in an ISO 13485 certified site, minimizing risk across the pharmaceutical value chain • Delivered specialized formulated solutions to meet stringent pharmaceutical packaging requirements • Provided global formulations transferrable from our three ISO 13485 certified facilities Mevopur™ Healthcare Concentrates KEY REQUIREMENTS WHY AVIENT?

LIGHTING MANUFACTURER S T R E E T L I G H T A R M • Limit corrosion • Replace metal insert, maintaining strength • Black color • UV resistance, as used for an outdoor application • Electrical isolation • Utilized simulation services from Avient Design to optimize the product’s design for performance and processability • Achieved required ageing test with the support from R&D and ADTS • Replaced the need to use a metal insert, reducing part weight, cost and simplifying the production process OnForce Long Glass Fiber Reinforced Polypropylene Composites KEY REQUIREMENTS WHY AVIENT?

POWER TOOL MANUFACTURER P O W E R T O O L B A T T E R Y P A C K • Non-Halogen to industry standards • Increased thermal conductivity • Good impact properties • Easy to process • Corporate color • Provided a non-halogenated solution for Bosch while increasing the thermal conductivity • Supported with regulatory and technical knowledge • Helped to source a UL-listed material from the EU for production in China with identical quality Maxxam NHFR Non-Halogen Flame Retardant Polyolefin Formulation KEY REQUIREMENTS WHY AVIENT?

G E N O M I C D I AG N O S T I C D E V I C E M A N U FAC T U R E R I N - V I T R O D I A G N O S T I C ( I V D ) D E V I C E MEVOPURTM Laser-Transmitting and Laser-Absorbing Pre-color Solution AV I E N T S O L U T I O N • Customized solutions - Quality-by-Design (QdB) approach • Optimized pigment / additive selection – good distribution in final part minimizes welding failure • Mitigated contamination and extractable risk on incoming raw material with control based on fingerprinting • Ensured uninterrupted supply from multiple ISO13485-2016 certified sites • Minimized risk of change with change control agreements W H Y AV I E N T K E Y R E Q U I R E M E N T S P R O D U C T I V I T Y & Q U A L I T Y • Good weldability, low rejection rate • Solutions in wide range of polymers, colors and transparency • Pre-tested ingredients to biocompatibility and extractable metals L E A R N M O R E https://www.avient.com/products/polymer-additives/performance-enhancement-additives/mevopur-functional-additives

Microsoft PowerPoint - Avient Q4 Earnings and 2021 Outlook PRINT AVIENT CORPORATION F O U R T H Q U A R T E R 2 0 2 0 R E S U L T S A N D 2 0 2 1 F I N A N C I A L G U I D A N C E (NYSE: AVNT) F E B R U A R Y 9 , 2 0 2 1 D I S C L A I M E R 2 Forward-Looking Statements In this presentation, statements that are not reported financial results or other historical information are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Whether an additional line at an existing manufacturing plant, or a new facility in a growing region, we ramp-up quickly and cost-efficiently. 22 Capex / Revenue 2021E (%) AV I E N T I S A SS E T L I G H T Avient Specialty Formulators Other Chemical/Specialty Companies 2 3 2 2 2 3 3 6 2 3 4 4 5 5 5 6 6 6 7 9 25 A vi e n t A vi e n t (E xc l. With the Clariant Masterbatch acquisition and divestment of the PP&S business, our exposure is now concentrated in less-cyclical and high-growth markets, with increased geographic diversification and a more specialized portfolio that can significantly expand EBITDA margins. 24 Avient reflects 2021 estimated EBITDA of $510M O U R VA LUATI O N V E R S U S P E E R S Avient Specialty Formulators Other Chemical/Specialty Companies 9.5 21.1 13.2 13.2 12.0 12.0 9.7 25.2 23.1 14.7 13.5 12.9 11.0 11.0 11.0 10.2 9.6 9.3 9.3 9.1 8.6 8.3 A vi e n t K W R A V Y R P M G C P P P G F U L A L B E C L H X L IF F F M C G R A B N R F O E A S H C E S C L U N V R E M N H U N K R A Median: 11.0xMedian: 12.6x S U M M A RY: W H Y I N V E S T I N AV I E N T ?

AVIENT CORPORATION T H I R D Q U A R T E R 2 0 2 3 R E S U L T S (NYSE: AVNT) N O V E M B E R 2 , 2 0 2 3 D I S C L A I M E R Forward-Looking Statements Certain statements contained in or incorporated by reference into this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Additionally, Adjusted EPS excludes the impact of special items and amortization expense associated with intangible assets. 2 O P E N I N G R E M A R K S B O B P A T T E R S O N C H A I R M A N , P R E S I D E N T A N D C E O Complementary technologies and customer relationships offer opportunity to advance commercial strategy Dyneema®, the world’s strongest fiber™, to accelerate growth of sustainable, ultralight and high performance applications AVIENT PROTECTIVE MATERIALS FIRST YEAR 4 Composites comprises over half of Specialty Engineered Materials, compared to 9% in 2016 Proven history of success in areas such as outdoor high performance, defense and sustainable solutions Composites 44% 56% 2023E Sales Collaboration & InnovationComposites as a % of SEM People & Culture Talented, passionate, and creative associates drive continued integration success and allow two cultures to come together as one Avient Lightweight Protective Laminates: PROJECTILE PROTECTION Dyneema® Fiber Solutions Cushioning + Fit + Comfort: LONG-TERM WEAR reSound™ Versaflex™ Thermoplastic Elastomers Strength + Durability + Light-Weighting: SOLID MOUNTING BRACKETS Nymax™ Bergamid™ Complēt™ Engineered Materials Durability + Lubricity: HELMET LATCHES Lubri-One™ Internally Lubricated Polymers Color Consistency and Weatherability CUSTOMIZED SPECIFICATIONS Avient Color and Additive Solutions Antennae Performance FAST, RELIABLE CONNECTIONS PREPERM™ Low-Loss Dielectric Thermoplastics AVIENT PROTECTIVE MATERIALS C R O S S S E L L I N G O P P O R T U N I T I E S Wired Connections CONSTANT COMMUNICATION Syncure™ Cross-linkable Wire & Cable Formulations5 6 AVIENT PROTECTIVE MATERIALS C R O S S S E L L I N G O P P O R T U N I T I E S 6 Q 3 P E R F O R M A N C E 15.4% 16.3% 2022 PF 2023 Results vs. PRIOR YEAR $790 $710 2022 2023 $107 $112 2022 2023 Sales Adjusted EBITDA (in millions) $0.42 $0.47 2022 PF 2023 Adjusted EPS (in millions) - 10% + 5% + 12% Sales Adjusted EBITDA Adjusted EPS 12 $112 $500 Q4 FY $0.47 $2.30 Q4 FY Q4 AND FULL YEAR 2023 GUIDANCE $710 $3,130 Q4 FY Sales Adjusted EBITDA Adjusted EPS 13 (in millions) (in millions) Guidance: Free Cash Flow $180 $180 Prior Guidance Guidance FREE CASH FLOW & INCREASED DIVIDEND 13th Consecutive Dividend Increase 0.16 0.26 0.42 0.58 0.79 0.85 0.99 1.03 2011 2013 2015 2017 2019 2021 2023 2024 14 S U S T A I N A B I L I T Y D AY R E C A P SUSTAINABILITY AS A GROWTH DRIVERLONG-TERM REVENUE GROWTH DRIVERS 60%+ Key Growth Drivers Sustainable Solutions Composites, Healthcare, Asia / LATAM Overlap Other (GDP Growth) Total Company Revenue Growth Drivers Long-Term Growth Rate Sustainable Solutions 8–12% Composites 8–10% Healthcare 8–10% Asia / LATAM 5% Other (GDP growth) 0–2% Avient 6% 17 SUSTAINABILITY TRENDS DRIVE LONG-TERM GROWTH 8-12% Long Term Growth 50 90 2022 2030 Medical Plastics Market Size (in $Billions) 2020 2030 Recycled Plastics Virgin Plastics Growing Demand for Recycled Content Avient Sustainable Solutions 18 46 2023 2032 Global Offshore Annual Wind Installations (in Gigawatts) Sources: McKinsey, Bloomberg, Grand View Research SUSTAINABILITY TRENDS DRIVE LONG-TERM GROWTH 18 • Transformative acquisitions combined with divestitures of more cyclical businesses have improved margins over 400 bps since 2018 • 20% long-term margin goal to be driven by key growth drivers, with sustainable solutions playing a meaningful role 5.4% 11.5% 16.0% 2006 2018 2023E Recovery Growth Drivers Strategic Objective 20%+ +1%+ +3%+ ADJUSTED EBITDA MARGIN EXPANSION 19 • 6% annualized long-term sales growth leveraging sustainable solutions, composites, healthcare, and emerging regions • Expand EBITDA margins to 20% • Deliver annual EBITDA and EPS growth of 10% and 15% • Maintain asset-light, 80% free cash flow conversion profile and be valued as a specialty formulator • Continue fostering our Great Place to Work® culture CRE AT ING A WORL D-CL AS S S US TAINABL E ORGANIZ AT ION 20 Reconciliation of Non-GAAP Financial Measures (Unaudited) (Dollars in millions, except for per share data) Senior management uses comparisons of adjusted net income from continuing operations attributable to Avient shareholders and diluted adjusted earnings per share (EPS) from continuing operations attributable to Avient shareholders, excluding special items, to assess performance and facilitate comparability of results.

Microsoft PowerPoint - AVNT M8 Investor Presentation AVIENT CORPORATION I N V E S T O R P R E S E N T A T I O N (NYSE: AVNT) A U G U S T 2 0 2 4 DISCLAIMER Forward-Looking Statements Certain statements contained in or incorporated by reference into this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. EBITDA Margin 16.9% +100 bps Q 2 2 0 2 4 R E S U L T S Q2 2024 PERFORMANCE VS. Q2 2023 ( T O TA L C O M PA N Y ) $824 $850 Q2 23 Q2 24 $131 $143 Q2 23 Q2 24 Sales Adjusted EBITDA (in millions) $0.63 $0.76 Q2 23 Q2 24 (in millions) Adjusted EBITDA Adjusted EPS 8 + 3% (+5% excluding FX) + 9% (+12% excluding FX) + 21% (+25% excluding FX) Sales 9 Q2 2 024 RESULTS – ORGA NI C SA LES BY REGION VS PY 9 US & Canada Latin America EMEA Asia +5% +4% +1% +19% Avient ex.